Life Technologies announces pharma partnering with Merck Serono on current and future companion diagnostics projects.
The value of the pharma partnering was undisclosed.
Merck Serono committed under a nonexclusive agreement to combining biomarkers identified by Merck Serono's translational research with Life Tech's platform technologies.
The companies will develop companion diagnostics concurrently with Merck's drug development programs.
The companies also agreed to develop an initial oncology diagnostic, while collaborating long-term on developing new diagnostics across a wide range of therapeutic areas and Life Tech instrument platforms that include next-generation sequencing, Sanger sequencing, qPCR, and flow cytometry.
If a development collaboration proves successful, it will be followed by a commercialization agreement under which Life Tech will commercialize a companion diagnostic in agreed-upon territories.
The companies also agreed to pursue simultaneous regulatory approvals for Merck Serono drugs and Life Tech companion diagnostics.
For further deal information visit Current Agreements (subscription required)
Read: more on Merck Serono company profile, recent partnering, M&A and financing news and articles
Report: Partnering Agreements with MerckKGaA/ Merck Serono 2005-2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity